Engineers Gate Manager LP Biocryst Pharmaceuticals Inc Transaction History

Engineers Gate Manager LP

$4.86 Billion
Q3 2024

A detailed history of Engineers Gate Manager LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 62,310 shares of BCRX stock, worth $466,701. This represents 0.01% of its overall portfolio holdings.

Number of Shares

62,310

Previous 28,980 115.01%

Holding current value

$466,701

Previous $179,000 164.25%

% of portfolio

0.01%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $213,645 - $289,637	33,330 Added 115.01%	62,310 $473,000
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $50,799 - $83,517	-12,300 Reduced 29.8%	28,980 $179,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $67,188 - $105,111	-13,740 Reduced 24.97%	41,280 $209,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $59,162 - $80,427	-11,880 Reduced 17.76%	55,020 $329,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $221,430 - $261,360	33,000 Added 97.35%	66,900 $473,000
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $234,496 - $296,826	-33,692 Reduced 49.85%	33,900 $238,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $536,680 - $800,289	67,592 New	67,592 $563,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $587,698 - $806,656	54,467 New	54,467 $686,000
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $494,792 - $614,573	-34,820 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $330,790 - $600,296	34,820 New	34,820 $551,000
Q2 2020 Aug 17, 2020	SELL	$1.9 - $5.61 $19,000 - $56,100	-10,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $16,000 - $41,100	10,000 New	10,000 $20,000

Others Institutions Holding BCRX

# of Institutions

280

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Account

Engineers Gate Manager LP Biocryst Pharmaceuticals Inc Transaction History